Business
XORTX Files New Provisional Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection
Compositions and Methods for Enhancing Anti-viral Therapies CALGARY, AB / ACCESSWIRE / M...
About this update from Xortx Therapeutics, Inc.
[{"type":"text","content":"XORTX Files New Provisional Patent to Treat and Protect Individuals Most at Risk to Severe Viral InfectionCompositions and Methods for Enhancing Anti-viral TherapiesCALGARY, AB / ACCESSWIRE / March 8, 2021 / XORTX Therapeutics Inc. (\"XORTX\" or the \"Company\") (CSE:XRX) (OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, with late-stage clinical programs, is pleased to announce the filing of a new provisional patent application entitled \"Compositions and Methods for Enhancing Anti-Viral Therapies\". This provisional patent was filed with the US Patent Office on Friday, March 5, 2021.In addition, studies of Coronavirus infections show that SARS and MERS and specifically COVID-19 can be frequently accompanied by pneumonia, acute kidney injury, proteinuria and hematuria1,2. Acute kidney injury (\"AKI\") has been identified as an independent risk factor for patients' in-hospital mortality due to COVID-19 as well as other Coronavirus infections2. Early reports suggested a lower incidence (between 3% to 9%) of AKI in those with COVID-19 infection2,3,4, however recent reports have shown a higher frequency of renal abnormalities. A study of 59 patients with COVID-19 found that 34% of patients developed massive albuminuria on the first day of admission and 63% developed proteinuria during their stay in hospital5. Associated with modest to severe COVID-19 infection is an increased risk of a hyper-inflammatory state, increased pro-coagulative state and bacterial infection - each can contribute to acute organ injury, and death.Dr. Allen Davidoff, President and CEO of XORTX stated, \"This new patent filing builds upon new and novel observations made in 2020 and 2021 regarding COVID-19 infection and why some individuals are at much greater risk than others. This patent aligns with the view that COVID-19 is likely to become endemic6 and the prediction that on a yearly basis millions of individuals worldwide will remain at risk. XORTX continues to focus on developing leading therapies to treat and protect individuals most susceptible to acute harm to a variety of body systems associated with viral and bacterial infection through our first-in-class programs.\"The focus of the patent is based on retrospective clinical data from XORTX scientific partners suggesting that an i...